- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06278454
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of NRT6008 Injection in Unresectable Locally Advanced Pancreatic Cancer (LAPC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Zhaoshen Li
- Phone Number: +8602131162338
- Email: zhsl@vip.163.com
Study Contact Backup
- Name: Zhaoshen Li
- Email: zhsl@vip.163.com
Study Locations
-
-
-
Chongqing, China
- Chongqing University Cancer Hospital
-
Contact:
- Weiqing Chen
-
Principal Investigator:
- Weiqing Chen
-
Tianjin, China
- Tianjin Medical University General Hospital
-
Contact:
- Bangmao Wang
-
Principal Investigator:
- Bangmao Wang
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Cancer Hospital
-
Principal Investigator:
- Suxia Luo
-
Contact:
- Suxia Luo
-
-
Jiangsu
-
Suzhou, Jiangsu, China
- Second Affiliated Hospital of Soochow University
-
Principal Investigator:
- Duanmin Hu
-
Contact:
- Duanmin Hu
-
-
Shanghai
-
Shanghai, Shanghai, China, +8602131162338
- Shanghai Changhai Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged ≥18 years, able to comprehend and sign an informed consent form;
- Diagnosed with pancreatic ductal adenocarcinoma confirmed histologically or cytologically;
- Evaluated as unresectable LAPC by the investigator, or having contraindications to surgery, or refusing surgical resection;
- ECOG performance status score ≤1;
- Expected survival ≥3 months;
- According to RECIST v1.1 criteria, there is only one measurable lesion in the pancreas confirmed by imaging, and the lesion has the shortest axis diameter ≥2.0 cm, the longest axis diameter ≤6.0 cm (based on baseline imaging);
- Adequate normal organ and marrow function as defined below: (1) Renal function: serum creatinine ≤1.5×ULN, or creatinine clearance ≥60 mL/min (calculated by the Cockcroft-Gault formula); (2) Liver function: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3×ULN; serum total bilirubin ≤1.5×ULN; (3) Bone marrow function [[no blood transfusion or granulocyte colony-stimulating factor (G-CSF), human thrombopoietin (TPO), or TPO receptor agonist treatment within 14 days prior to signing informed consent]: neutrophils ≥1.5×10^9/L, hemoglobin ≥100 g/L, platelets ≥80×10^9/L; (4) Coagulation function: International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN;
- Female and male participants of reproductive age must voluntarily agree to practice strict and effective contraception after signing the informed consent form, during the study period, and within 12 months after administration of the investigational drug. Males are prohibited from donating sperm during this period. Female participants of reproductive age must have a negative pregnancy test result during the screening period and within 24 hours before administration of the investigational drug.
Exclusion Criteria:
- Allergic to the investigational drug NRT6008 injection itself or any of its components;
- Contraindications to any of the three optional systemic chemotherapy regimens in this study judged by investigators;
- Previous anti-tumor treatments for pancreatic cancer, including but not limited to chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. Except for discontinuation of traditional chinese medicine or herbal medicine for at least 7 days prior to the screening period;
- Contraindications to anesthesia;
- History of any other malignant tumors within 5 years before receiving investigational drug treatment, except for cases of cured non-melanoma skin cancer, cervical carcinoma in situ, or basal cell carcinoma of the skin, Stage I Grade 1 endometrial carcinoma, or thyroid cancer;
- Presence or suspected presence of distant metastases according to imaging;
- Pregnant or lactating females;
- Participants assessed by the investigators to be at high risk or had difficulty in operation for EUS-FNI procedures;
- Evidence of radiographic invasion into stomach,duodenum or peritoneum;
- Participants with chronic diseases that are actively treated but not well controlled, such as primary hypertension (e.g. >150/100 mmHg), diabetes (meeting diagnostic criteria for diabetes, e.g. fasting blood glucose ≥7.0 mmol/L, and/or postprandial blood glucose ≥11.1 mmol/L), etc.;
- Within 6 months prior to the screening period, occurrence of acute or chronic pancreatitis, severe gastrointestinal bleeding, severe cardiovascular diseases (including but not limited to stroke, unstable angina), or occurrence of acute infections requiring systemic treatment within 2 weeks before the screening period;
- Participated in other interventional clinical trials within 30 days prior to screening period;
- Positive for human immunodeficiency virus (HIV) antibodies;
- Positive for hepatitis B virus (HBV) surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb), HBV DNA testing required, participants with HBV-DNA levels below the lower limit of the reference range or < 500 IU/mL will be eligible for inclusion in this study (use of antiviral drugs during the study period is required);
- Positive for hepatitis C virus (HCV) antibodies, HCV RNA testing required, participants with negative HCV RNA results will be eligible for inclusion in this study;
- Participants with syphilis infection or active tuberculosis;
- Other reasons deemed unsuitable for participation in this trial by the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NRT6008 Injection
In this study, participants shall receive NRT6008 injection in combination with chemotherapy.
|
-Systematic chemotherapy The chemotherapy regimen is selected by the investigators at the consideration of participants' conditions, with either GN or (m)FOLFIRINOX. GN: gemcitabine 1000 mg/m^2 and nab-paclitaxel 125 mg/m^2, every 21 days (3 weeks/cycle). FOLFIRINOX: oxaliplatin 85 mg/m^2, irinotecan 180 mg/m^2, leucovorin 400 mg/m^2 and fluorouracil 400 mg/m^2 given as a bolus followed by 2400 mg/m^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle). mFOLFIRINOX: oxaliplatin 85 mg/m^2, irinotecan 180 mg/m^2, leucovorin 400 mg/m^2, and fluorouracil 2400 mg/m^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle). -NRT6008 injection administration: NRT6008 injection is implanted into pancreatic tumor via endoscopic ultrasound (EUS)-guided fine-needle injection, at the instruction of the investigator. The dose of NRT6008 injection is determined by tumor volume and estimated tumor average absorbed dose. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD) or the recommended phase Ⅱ dose (RP2D)
Time Frame: 28 days after NRT6008 administration
|
Optimal dose for NRT6008 injection
|
28 days after NRT6008 administration
|
Dose-limiting toxicity (DLT)
Time Frame: 28 days after NRT6008 administration
|
Incidence rate of DLT
|
28 days after NRT6008 administration
|
Adverse events (AE) and severe adverse events (SAE)
Time Frame: Up to 52 weeks
|
Incidence rate and severity of AE and SAE
|
Up to 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to 52 weeks
|
According to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1 (evaluated by the investigator and Independent Review Committee respectively)
|
Up to 52 weeks
|
Duration of response (DOR)
Time Frame: Up to 52 weeks
|
According to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1 (evaluated by the investigator and Independent Review Committee respectively)
|
Up to 52 weeks
|
Progression-free survival (PFS)
Time Frame: Up to 52 weeks
|
According to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1 (evaluated by the investigator and Independent Review Committee respectively)
|
Up to 52 weeks
|
Overall survival (OS)
Time Frame: Up to 52 weeks
|
How long the participant lives after the administration
|
Up to 52 weeks
|
Resection rate (R0 and R1)
Time Frame: Up to 52 weeks
|
R0 (≥1 mm margin), R1 (<1 mm clearance)
|
Up to 52 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of tumor biomarkers
Time Frame: Up to 52 weeks
|
Changes of tumor biomarkers through the study
|
Up to 52 weeks
|
Numeric rating scale (NRS) of pain
Time Frame: Up to 52 weeks
|
Changes of NRS score
|
Up to 52 weeks
|
Distribution of NRT6008 injection in human body and radioactivity of biological samples
Time Frame: Up to 48 hours
|
Distribution of NRT6008 injection in human body and radioactivity of Yttrium-90 in blood, urine, and feces (if available)
|
Up to 48 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Zhaoshen Li, Changhai Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NrtPac-1
- CTR20240312 (Other Identifier: Center for Drug Evaluation, NMPA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unresectable Pancreatic Cancer
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; National Cancer Institute (NCI); Syndax PharmaceuticalsCompletedPancreatic Cancer | Cholangiocarcinoma | Metastatic Pancreatic Cancer | Unresectable Pancreatic Cancer | Metastatic Cholangiocarcinoma | Unresectable CholangiocarcinomaUnited States
-
Centre Hospitalier Universitaire DijonCompletedUnresectable Pancreatic AdenocarcinomaFrance
-
Memorial Sloan Kettering Cancer CenterCompletedPancreatic Cancer | Unresectable Biliary-pancreatic MalignanciesUnited States
-
National Cancer Institute (NCI)SuspendedStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Unresectable Pancreatic AdenocarcinomaUnited States
-
Istituto Scientifico Romagnolo per lo Studio e...CompletedUnresectable Pancreatic Cancer | Locally Advanced Pancreatic Cancer | Nonmetastatic Pancreatic CancerItaly
-
Meabco A/SMeddoc; Norwegian University of Life SciencesCompletedMetastatic Pancreatic Cancer | Unresectable Pancreatic CancerEgypt
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
Dana-Farber Cancer InstitutePatient-Centered Outcomes Research Institute; National Cancer Institute (NCI); Alliance for Clinical Trials in OncologyCompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
Galera Therapeutics, Inc.TerminatedUnresectable Pancreatic Cancer | Borderline Resectable Pancreatic Cancer | SBRTUnited States, France, United Kingdom, Canada
-
Devalingam MahalingamAmgenWithdrawnPancreatic Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic Cancer | KRAS P.G12CUnited States
Clinical Trials on NRT6008 Injection + Systematic chemotherapy
-
Fudan UniversityRecruitingHER2-negative Breast Cancer | Leptomeningeal MetastasisChina
-
Sun Yat-sen UniversityNot yet recruitingColorectal Neoplasms | Colorectal Cancer | Peritoneal Neoplasms | Colorectal Cancer Metastatic | Chemotherapy Effect | Cytoreductive Surgery | Peritoneal Cancer | Peritoneal Metastases | Hyperthermic Intraperitoneal ChemotherapyChina
-
First Affiliated Hospital of Harbin Medical UniversityCompletedHead and Neck Cancer | RadiotherapyChina
-
Jie LiMinistry of Science and Technology of the People´s Republic of China; Institute...Unknown
-
3D Medicines (Sichuan) Co., Ltd.RecruitingNon-small Cell Lung CancerChina
-
Peng ZhangRecruiting
-
Shanghai Junshi Bioscience Co., Ltd.CompletedTreatment-naive Advanced Non-small Cell Lung CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Xiaonan CuiUnknownGastrointestinal NeoplasmsChina
-
FeRxCompletedMelanoma | Sarcoma | Stomach Neoplasms | Gastrointestinal Neoplasms | Breast Neoplasms | Lung Neoplasms | Liver Neoplasms | Colorectal Neoplasms | Pancreatic Neoplasms | Esophageal Neoplasms | Metastases, Neoplasm | CholangiocarcinomaUnited States, Germany